Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Topical corticosteroids are the preferred first treatment for children with Alopecia Areata.

Calcium signals and SHH guide the direction of feather growth in chicken skin.

Women with scarring alopecia are less likely to have used hormone replacement therapy or oral contraceptives compared to those with female pattern hair loss.

The model and estimator can predict drug exposure in kidney transplant patients well.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.

A boy's growth and immune problems were caused by a new mutation in the STAT5B gene.

Ritlecitinib is an effective new treatment for Alopecia Areata.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

A new hydrogel treatment reduces inflammation and promotes hair growth in alopecia areata.

A new hydrogel treatment reduces inflammation and promotes hair growth in alopecia areata.

OR-101 shows promise for treating alopecia areata by improving hair growth.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

Quercetin and kaempferol may be effective and safe natural treatments for hair loss.

Quercetin and kaempferol may be effective and safe natural treatments for hair loss.

The Tru9I variant in the VDR gene may influence alopecia areata risk and vitamin D levels.

OR101 may effectively treat atopic dermatitis and similar skin conditions.

Alopecia areata involves persistent gene abnormalities and immune activity, even in regrown hair, suggesting a risk of relapse.

Baricitinib showed mixed results in treating alopecia areata in children, with some improvement but also side effects.

Alopecia areata patients may have higher cardiovascular risk factors, so screening for metabolic syndrome components is suggested.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Upadacitinib effectively treats pyoderma gangrenosum.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

The treatment showed significant hair regrowth in alopecia areata patients without side effects.

The research suggests that immune cells and a specific type of cell death called ferroptosis are involved in Frontal fibrosis alopecia.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.